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Breast Cancer Deaths Averted Over 3 Decades
R. Edward Hendrick, PhD 1; Jay A. Baker, MD2; and Mark A. Helvie, MD3
BACKGROUND: From 1975 to 1990, female breast cancer mortality rates in the United States increased by 0.4% per year. Since 1990, 
breast cancer mortality rates have fallen between 1.8% and 3.4% per year, a decrease that is attributed to increased mammography 
screening and improved treatment. METHODS: The authors used age-adjusted female breast cancer mortality rate and population 
data from the Surveillance, Epidemiology, and End Results (SEER) program to estimate the number of breast cancer deaths averted 
by screening mammography and improved treatment since 1989. Four different assumptions regarding background mortality rates 
(in the absence of screening mammography and improved treatment) were used to estimate deaths averted for women aged 40 to 
84 years by taking the difference between SEER-reported mortality rates and background mortality rates for each 5-year age group, 
multiplied by the population for each 5-year age group. SEER data were used to estimate annual and cumulative breast cancer 
deaths averted in 2012 and 2015 and extrapolated SEER data were used to estimate deaths averted in 2018. RESULTS: The number 
of single-year breast cancer deaths averted ranged from 20,860 to 33,842 in 2012, from 23,703 to 39,415 in 2015, and from 27,083 
to 45,726 in 2018. Breast cancer mortality reductions ranged from 38.6% to 50.5% in 2012, from 41.5% to 54.2% in 2015, and from 
45.3% to 58.3% in 2018. Cumulative breast cancer deaths averted since 1989 ranged from 237,234 to 370,402 in 2012, from 305,934 
to 483,435 in 2015, and from 384,046 to 614,484 in 2018. CONCLUSIONS: Since 1989, between 384,000 and 614,500 breast 
cancer deaths have been averted through the use of mammography screening and improved treatment. Cancer 2019;125:1482-1488. 
© 2019 American Cancer Society. 
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INTRODUCTION
Since 1969, the National Cancer Institute (NCI)’s Surveillance, Epidemiology, and End Results (SEER) program has 
collected breast cancer incidence and mortality data for the United States.1 The most recent data extend to 2015. Analysis 
by the NCI indicates that breast cancer mortality rates for US females of all ages increased by a statistically significant 
0.4% per year from 1975 to 1990.2 Mortality rates then decreased by a statistically significant 1.8% per year from 1990 
to 1995, 3.4% per year from 1995 to 1998, and 1.8% per year from 1998 to 2015.2 From 1989 to 2015, age-adjusted 
female breast cancer mortality rates among women aged 40 to 84 years are reported to have decreased by 41.6% 
(Fig. 1).3 This decrease has been attributed to the increased use of screening mammography combined with improved 
breast cancer treatment.4-6
Screening mammography became widely available in the mid-1980s, and its use increased until the early 2000s.4-7 
According to self-reported data collected in the Center for Disease Control and Prevention’s National Health Interview 
Survey,7 in 1987, approximately 29% of women aged >40 years reported having undergone mammography within the 
previous 24 months. This figure rose to 70% in 2000, and then dropped to 64% in 2015. The National Health Interview 
Survey overestimates screening mammography use for 2 reasons. First, it does not distinguish between screening and 
diagnostic mammography. According to data from the US Breast Cancer Surveillance Consortium that were collected 
between 1994 and 2009, approximately 17% of mammographies were performed for reasons other than screening.8 
Second, according to the study by Cronin et al,9 self-reported mammography use in the previous 2 years overestimated 
screening mammography use in that period by 14% to 27%. Adjusting for such factors, Berry et al estimated that when 
screening mammography use was at its peak in the year 2000, approximately 25% of US women aged >40 years received 
annual screening mammography, another 25% received biennial screening mammography, and the remaining 50% of 
women underwent irregular screening or no screening at all.4
The Cancer Intervention and Surveillance Modeling Network (CISNET), a consortium of NCI-sponsored inves-
tigators, has attempted to use models of breast cancer incidence and mortality, along with mammography screening and 
treatment trends, to separate the effects of screening mammography and adjuvant therapy on the reduction in breast 
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cancer deaths.4-6 Their models estimated that screening 
mammography was responsible for 28% to 65% of the 
reduction in breast cancer deaths in the year 2000, with a 
median estimate of 46%, and the remainder of the reduc-
tion was due to advances in treatment.4 These estimates 
assumed that nearly all women diagnosed with breast 
cancer underwent treatment, but only approximately 
one-half of women aged >40 years underwent screen-
ing mammography annually or biennially.4,5 Based on 
2 CISNET models, Munoz et al estimated that in the 
year 2000, with 100% compliance to screening mam-
mography, screening would be responsible for 69% to 
74% of breast cancer deaths averted.6 A 2018 CISNET 
update by Plevritis et al, based on an assumed compliance 
rate of 50% to 55% with either annual or biennial screen-
ing mammography, estimated that in 2012 screening 
mammography was responsible for 37% of the estimated 
mortality reduction (range over 6 models, 26%-51%).5 
Clearly, the relative contribution of screening to mortality 
reduction estimates depends strongly on assumed screen-
ing mammography (and treatment) compliance rates.
DeSantis et al estimated the number of female 
breast cancer deaths averted because of screening and 
improved treatment from 1989 to 2012 to be 249,000, 
based on the assumption that, absent increased screen-
ing or improved treatment, the death rate would have 
remained at 1989 levels.10 Although this assumption is 
the simplest in assessing changes since 1989, it ignores 
the steadily increasing background mortality trends 
prior to 1989. Just as estimates of overdiagnosis over 
the past 30 years are highly sensitive to assumptions of 
background breast cancer incidence rates,11,12 estimates 
of breast cancer deaths averted since 1989 are similarly 
sensitive to assumptions regarding breast cancer mor-
tality rates in the absence of screening mammography 
and improved treatment, referred to herein as back-
ground mortality rates.
The goal of the current study was to estimate the 
number of breast cancer deaths averted since 1989 due to 
the collective effects of both screening mammography and 
improved treatment. The current analysis extended the es-
timates of DeSantis et al10 by using several different meth-
ods to estimate background breast cancer mortality rates, 
including methods based on mortality rate trends prior 
to 1989. We also estimated percentage mortality reduc-
tions for US women overall and by 5-year age groups. The 
current analysis did not attempt to estimate the separate 
contributions of mammography screening and adjuvant 
treatment with regard to breast cancer deaths averted.
MATERIALS AND METHODS
All data used in the current analysis were anonymized, 
publicly available data, and therefore required no institu-
tional review board approval. Breast cancer deaths averted 
in US women since 1989 were estimated using age-specific 
5-year breast cancer mortality data and female popula-
tion data for US women aged 40 to 84 years. Female age- 
adjusted breast cancer mortality rates (Fig. 2) and popula-
tion data for each 5-year age group are available from 1969 
to 2015 from the latest SEER database mortality tables 
(SEER*Stat Software, Version 8.3.5).3 For the years 2016 
through 2018, a linear least squares fit to breast cancer 
mortality rates from the previous 10 years, 2006 through 
2015, was used to extrapolate mortality rates for 3 ad-
ditional years, 2016 to 2018, for each 5-year age group. 
Analysis of residuals was performed to establish that linear 
fits were appropriate. Extrapolated mortality rates were 
included as the last 3 data points for each age group in 
Figure 2. Female population data for 2016 for each 5-year 
age group aged 40 to 84 years were taken from US Census 
estimates as of July 1, 2016,13 and for 2017 and 2018 from 
US female population estimates by age.14
Four different methods were used to estimate back-
ground mortality rates for female breast cancer from 
1990 through 2018:
First, following the study by DeSantis et al,10 
 background mortality rates were assumed to be flat since 
1989. This simple assumption assesses changes since 
1989, when breast cancer mortality rates were at their 
peak, but ignores background mortality rate trends prior 
Figure 1. Age-adjusted US breast cancer mortality rates (per 
100,000 women) for women aged 40 to 84 years by year 
from 1969 through 2015 from the Surveillance, Epidemiology, 
and End Results (SEER) database.
???????????
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to 1989. Prior to 1989, background mortality rates in-
creased overall, most likely due to preceding increases in 
breast cancer incidence rates. The 3 assumptions that fol-
low attempt to account for those increasing background 
mortality trends, although in different ways.
The second method was to assume that background 
mortality rates after 1989 continued their previously 
steady increase of 0.4% per year as was observed from 
1975 to 1990, based on joinpoint analysis by Noone et al.2 
The extrapolation of joinpoint trends to estimate mortal-
ity rates has precedent in the peer-reviewed literature.15,16
In the third method, background mortality rates 
after 1989 were estimated for each 5-year age group using 
the change in mortality rates for that age group prior to 
1990. Specifically, for each 5-year age group from ages 
40 to 84 years, the trend over the previous 11 years, 1979 
through 1989, was determined by a best linear fit to 
SEER mortality rate data and the resulting background 
trend was assumed to persist from 1990 to 2012, 2015, 
and 2018.15,16
Following the study by Cronin et al,17 which used 
7 CISNET models to estimate background mortality 
rates in the absence of screening or treatment, the fourth 
method was to assume that background mortality rates 
increased by 0.94% per year since 1989. The 7 models 
used by Cronin et al17 estimated that between 1975 and 
2000, in the absence of screening or treatment, breast 
cancer mortality rates would have increased by a mean 
of 12.7 deaths per 100,000 women (median, 14.7 deaths 
per 100,000 women [range, 5.6-15.9 deaths per 100,000 
women]) compared with a 1975 breast cancer mortality 
rate of 48.2 deaths per 100,000 women. Their mean 
background mortality rate estimate was an increase of 
26.2% over 25 years or 0.94% per year. We extrapolated 
this result to extend to 2012, 2015, and 2018.
Figure 3 illustrates these 4 different background 
mortality rate assumptions for a single 5-year age group, 
women aged 65 to 69 years. For each of these 4 methods, 
we assumed that the background mortality rate change 
continued from 1989 to different end dates of 2012, 2015, 
and 2018. Estimates for 2012 and 2015 are based entirely 
on SEER breast cancer mortality rate and population 
data. Estimates for 2018 are based on extrapolations of 
SEER breast cancer mortality rates and census projec-
tions of US female population data from 2016 to 2018.
Breast cancer deaths averted in a given year for each 
5-year age group were determined by taking the differ-
ence between background mortality rates and measured 
rates for the years 1990 through 2015 (or extrapolated 
rates for years 2016-2018) per 100,000 women and multi-
plying by the US female population that year (in 100,000 
populations) in that 5-year age group. Breast cancer 
deaths averted in a given year were determined by sum-
ming over all 5-year age groups between ages 40 and 84 
years. Cumulative breast cancer deaths averted since 1989 
were determined by summing deaths averted in each year 
from 1990 to the endpoints of 2012, 2015, and 2018.
Percentage mortality reductions in 2012, 2015, 
and 2018 were determined by dividing the estimated 
breast cancer deaths averted in a given year by the total 
estimated breast cancer deaths without screening or im-
proved treatment (the sum of known breast cancer deaths 
in a given year plus the estimated breast cancer deaths 
averted in that year) multiplied by 100%:
Known breast cancer deaths each year for women 
aged 40 to 84 years were taken from the SEER mortality 
database up to 2015.3 For the year 2018, breast cancer 
deaths in each 5-year age group were estimated by mul-
tiplying the linearly extrapolated breast cancer death rate 
for 2018 for each 5-year age group by the 2018 estimated 
female population for each 5-year age group.13
RESULTS
Single-year breast cancer deaths averted in US women 
aged 40 to 84 years by both mammography screening 
%mortality reduction = (breast cancer deaths averted × 100%)∕
(known breast cancer deaths +breast cancer deaths averted)
Figure 2. Age-adjusted breast cancer mortality rates (per 
100,000 women) by year for each 5-year age group of 
women aged 40 to 84 years. Rates shown for 2016 through 
2018 in each age group are linear extrapolations of mortality 
rate trends for that age group from 2006 to 2015.
????????????
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and improved treatment since 1989 are shown in Table 1 
for the years 2012, 2015, and 2018. In 2018, estimates 
ranged from 27,083 to 45,726 breast cancer deaths 
averted. Also shown in Table 1 are percentage mortal-
ity reductions for 2012, 2015, and 2018 based on SEER-
reported breast cancer deaths specific to each of those 
3 years. In 2018, the percentage mortality reduction esti-
mates for women aged 40 to 84 years ranged from 45.3% 
to 58.3%.
Cumulative breast cancer deaths averted in US 
women aged 40 to 84 years by both screening and im-
proved treatment beginning in 1990 and ending in 2012, 
2015, and 2018 are shown in Table 2. In 2018, estimates 
ranged from 384,046 to 614,484 breast cancer deaths 
averted. Figure 4 illustrates the estimated cumulative 
breast cancer deaths averted by year since 1989 for the 
4 different assumptions about background breast cancer 
mortality trends. Table 2 and Figure 4 show that the as-
sumption of a flat background since 1989 yields the lowest 
estimate of breast cancer deaths averted by screening and 
improved treatment. Table 2 and Figure 4 show approx-
imately similar results for breast cancer deaths averted 
since 1989 based on a background trend of a 0.4% per 
year increase and a background trend based on individual 
5-year age group mortality trends prior to 1990.
Table 3 shows percentage mortality decreases 
for each 5-year age group and the entire age range of 
women aged 40 to 84 years based on our 4 different 
Figure 3. Surveillance, Epidemiology, and End Results (SEER) age-adjusted mortality rates (per 100,000 women) for women 
aged 65 to 69 years by year from 1975 through 2015 (blue data points). Dark red data points represent linear extrapolation 
of the mortality rate to 2016 through 2018 based on the trend from 2006 through 2015. Solid lines represent the 4 different 
assumptions regarding background (Bkgd) mortality rate trends since 1989. Blue indicates increasing by 0.94% per year since 
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TABLE 1. Single-Year Breast Cancer Deaths Averted and Percentage Mortality Reduction in US Women 
Aged 40 to 84 Years
Year
Background Mortality Rate Assumption
Background Mortality 
Rate Flat Since 1989
Background Mortality 
Rate Increase of 0.4% 
per Year Since 1989
5-Year Age Group 
Background Mortality 
Rate Trends:  
1979 to 1989
Background Mortality 
Rate Increase of 
0.94% per Year Since 
1989
2012 20,860 26,060 27,801 33,842
38.6% 44.0% 45.6% 50.5%
2015 23,703 29,943 32,329 39,415
41.5% 47.3% 49.2% 54.2%
2018 27,083 34,424 37,769 45,726
45.3% 51.3% 53.6% 58.3%
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TABLE 2. Cumulative Breast Cancer Deaths Averted in US Women Aged 40 to 84 Years Since 1989
Background Mortality Rate Assumption
Year Range
Background Mortality 
Rate Flat Since 1989
Background Mortality 
Rate Increase of 0.4% 
per Year Since 1989





Rate Increase of 0.94% 
per Year Since 1989
1990-2012 237,234 291,579 312,788 370,402
1990-2015 305,934 377,933 405,499 483,435
1990-2018 384,046 476,947 513,320 614,484
Figure 4. Cumulative breast cancer deaths averted for women aged 40 to 84 years under 4 different assumptions regarding 
background (Bkgd) mortality rate trends since 1989.
??????????????????????
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TABLE 3. Percentage Mortality Reduction in 2012, 2015, and 2018 by 5-Year Age Groups and Ages  
40 to 84 Years Based on 4 Different Assumptions Regarding Expected Background Mortality Rates in the 
Absence of Screening and Advances in Treatment
Age Range, Years
Background Flat Since 
1989
Background Increase of 
0.4% per Year Since 
1989
Background With 5-Year 
Age Group Trends
Background Increase of 
0.94% per Year Since 
1989
2012 2015 2018a 2012 2015 2018a 2012 2015 2018a 2012 2015 2018a
40-44 47.0% 51.9% 52.7% 51.6% 56.7% 57.8% 44.5% 49.7% 50.3% 57.2% 62.3% 63.9%
45-49 43.9% 49.4% 53.0% 48.8% 54.4% 58.1% 42.9% 48.4% 52.0% 54.8% 60.4% 64.2%
50-54 46.4% 48.4% 50.9% 51.1% 53.5% 56.3% 36.2% 37.0% 38.6% 56.8% 59.5% 62.6%
55-59 43.6% 45.5% 51.5% 48.6% 50.9% 56.8% 40.6% 42.1% 48.0% 54.6% 57.3% 63.1%
60-64 41.5% 44.8% 50.2% 46.6% 50.3% 55.6% 52.8% 56.4% 61.4% 52.8% 56.7% 62.0%
65-69 38.3% 42.2% 45.3% 43.7% 47.9% 51.3% 46.3% 50.6% 54.1% 50.2% 54.7% 58.3%
70-74 35.6% 37.2% 40.1% 41.2% 43.4% 46.7% 51.7% 54.4% 57.8% 48.0% 50.7% 54.4%
75-79 30.4% 33.2% 37.1% 36.5% 39.8% 44.0% 46.2% 50.0% 54.3% 43.9% 47.6% 52.0%
80-84 22.5% 26.3% 30.8% 29.3% 33.6% 38.4% 39.7% 44.3% 49.1% 37.5% 42.2% 47.3%
40-84 38.6% 41.5% 45.3% 44.0% 47.3% 51.3% 45.6% 49.2% 53.6% 50.5% 54.2% 58.3%
aPercentage mortality decreases for 2016 through 2018 are based on linear extrapolations of mortality rate trends from 2006 to 2015.
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assumptions regarding expected background mortal-
ity in the absence of screening or advances in treat-
ment. The first assumption of mortality rates being 
unchanged since 1989 represents the known mortality 
decrease since 1989 in 2012 and 2015, and the esti-
mated decrease since 1989 in 2018.
DISCUSSION
The current study demonstrates that estimates of the 
number of breast cancer deaths averted due to screening 
and improved treatment depend strongly on specific as-
sumptions regarding background mortality rate trends in 
the absence of screening and advances in treatment. For 
example, estimates of mortality reduction in 2015 ranged 
from 41.5% to 54.2% and estimates of breast cancer 
deaths averted in that single year ranged from 23,703 to 
39,415 across the 4 different assumptions regarding back-
ground mortality rates. Likewise, the cumulative breast 
cancer deaths averted from 1990 to 2015 ranged from 
>305,000 women to >483,000 women depending on 
background mortality assumptions. Extrapolating results 
to 2018 shows that the cumulative breast cancer deaths 
averted since 1989 ranged from >384,000 to >614,000.
The assumption that background mortality rates 
are f lat in the absence of screening mammography and 
improved treatment since 1989 likely underestimates 
the number of breast cancer deaths averted. This is 
because, similar to breast cancer incidence rates, US 
breast cancer mortality rates were increasing prior to 
1990.2 Background mortality rate estimates of the sec-
ond and third methods also may underestimate the 
background rate because modern treatment advances 
with adjuvant chemotherapy and hormonal therapy 
already had entered clinical practice in the 1980s.4,5 
Both treatments had likely begun to suppress mortality 
rates by 1989. The successful application of hormonal 
therapy and adjuvant chemotherapy in the 1980s likely 
began to reduce mortality shortly after their intro-
duction among women already diagnosed with breast 
cancer. Screening mammography, although entering 
widespread clinical practice in the mid-1980s, was 
shown by randomized controlled trials to require 5 to 
7 years to demonstrate an evident mortality reduction 
due to the longer interval between screen detection and 
prevented death.18
The majority of other developed countries also ex-
perienced increasing breast cancer mortality rates prior 
to the adoption of widespread screening mammography 
in the 1980s and 1990s.19 We believe the best estimates 
of breast cancer deaths averted are those that take into 
account these background increases. Thus, we estimate 
that over the last 3 decades, in excess of one-half mil-
lion breast cancer deaths have been averted by screening 
mammography and improved treatment.
CISNET modeling results reported in the study by 
Plevritis et al estimated that in 2012, the mortality reduc-
tion due to both mammography screening and advances 
in treatment for US women aged 30 to 79 years was 
49%.5 Our estimate for the mortality reduction in 2012 
for women aged 40 to 84 years based on 5-year age group 
background trends was 45.6%, which we believe is in rea-
sonable agreement with the estimate of Plevritis et al.5 If we 
assume the same background mortality increase of 0.94% 
per year that was the mean estimate by CISNET models 
in the study by Cronin et al,17 our estimated mortality re-
duction in women aged 40 to 84 years in 2012 is 50.5%, 
which is in good agreement with the CISNET estimate 
for women aged 30 to 79 years. Our estimate of 237,234 
deaths averted from 1990 through 2012, assuming a flat 
background, also is in good agreement with the study of 
DeSantis et al, which had an estimate of 249,000 deaths 
averted during the same period.10 The difference between 
these 2 estimates is that DeSantis et al10 estimated breast 
cancer deaths averted in US women of all ages, whereas we 
restricted our estimate to women aged 40 to 84 years.
One limitation of the current study is that SEER 
breast cancer incidence data do not specify whether a 
woman attended mammography screening within 1 year 
of her breast cancer diagnosis. Although nearly all US 
women diagnosed with breast cancer receive treatment, 
only approximately one-half of those aged >40 years 
undergo either annual or biennial screening.4,5,9 Thus, 
the current analysis did not estimate breast cancer deaths 
averted from screening all age-eligible US women, as 
other studies have.6,20 In addition, the current analysis 
made no attempt to estimate the separate contributions of 
screening versus advances in treatment, as others have.4-6
Another limitation of the current study is that it 
estimated the number of breast cancer deaths averted 
and percentage mortality reduction since 1989, not the 
full number of breast cancer deaths averted by screen-
ing mammography and treatment. Although the onset of 
widespread screening mammography in the mid-1980s 
did not begin to affect breast cancer mortality rates until 
the early 1990s, treatment improvements such as tamox-
ifen and advances in surgical therapy were ongoing and 
averting breast cancer deaths prior to 1989.
However, based on SEER mortality data and the 
estimates in the current study, we believe that hundreds 
of thousands of women’s lives, likely in excess of one-half 
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million by 2018, have been saved by the use of screening 
mammography and new developments in breast cancer 
treatment since 1989.
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